CLINICOPATHOLOGICAL CORRELATION OF P53 EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE ADENOCARCINOMA
DOI:
https://doi.org/10.22159/ajpcr.2024v17i11.52524Keywords:
Prostate tumors, Gleason score, immunohistochemistry, molecular markerAbstract
Objective: To assess clinicopathological parameters in patients with benign prostatic hyperplasia and prostate adenocarcinoma, and evaluate their correlation with p53 overexpression in these prostatic conditions.
Methods: The present ambispective study was conducted in the Department of Pathology in a tertiary care hospital of Northern India from 2022 to 2024. This study included prostatic trucut biopsies, transurethral prostatic resection (TURP) chips, and radical prostatectomy specimens from patients with benign prostatic hyperplasia (BPH) or prostatic adenocarcinoma. Tissue samples were processed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for histopathological evaluation. Immunohistochemical (IHC) analysis was performed to assess p53 expression using the GenomeMe antibody. Data on age, histological type and histological grade were collected. Statistical analysis included Chi-square test was conducted to evaluate associations between p53 overexpression and clinicopathological parameters.
Results: The study analyzed 50 cases, revealing significantly higher p53 expression in prostatic adenocarcinoma compared to BPH. The majority of participants were aged between 61-70 years (46%). There were 50% patients with adenocarcinoma, 26% with BPH, 20% with BPH and chronic prostatitis, and 4% with BPH with prostatic intraepithelial neoplasia. There were strong associations between p53 overexpression and specific diagnoses, histological type and histological grade (Gleason scores) in prostate cancer.
Conclusion: The study findings suggest that p53 overexpression is closely linked to malignant prostate conditions and could potentially serve as a valuable biomarker for distinguishing between benign and malignant prostatic diseases, as well as predicting tumor aggressiveness.
Downloads
References
Albertsen PC. Benign and malignant diseases of the prostate. In: Rosenthal RA, Zenilman ME, Katlic MR, editors. Principles and practice of geriatric surgery. New York: Springer; 2001. p. 806-16.
Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. In: Treasure Island, FL: StatPearls Publishing; 2024. StatPearls. p. 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558920
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89. doi: 10.14740/wjon1191, PMID 31068988
Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993;85(20):1657-69. doi: 10.1093/jnci/85.20.1657, PMID 7692074
Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res. 1999;5(8):2082-8. PMID 10473090
Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 2000;60(24):6788- 93. PMID 11156366
Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974. doi: 10.1038/s41419-022-05408-1, PMID 36400749
Williams AB, Schumacher B. p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 2016;6(5):a026070. doi: 10.1101/ cshperspect.a026070, PMID 27048304
Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: Part 1: Epidemiology, pathology, and screening. Fed Pract. 2015;32(Suppl 4):41S-4S. PMID 30766120
Bhat G, Ahamed MA, Saroha N, Prasad G. Clinicopathological correlation of p53 expression in benign prostatic hyperplasia and prostate adenocarcinoma. Indian J Pathol Oncol. 2023;9(1):60-4.
Verma R, Gupta V, Singh J, Verma M, Gupta G, Gupta S, et al. Significance of p53 and Ki-67 expression in prostate cancer. Urol Ann. 2015;7(4):488-93. doi: 10.4103/0974-7796.158507, PMID 26692671
Schitcu VH, Raduly L, Zanoaga O, Jurj A, Munteanu VC, Budisan L, et al. TP53 gene 86 implications in prostate cancer evolution: Potential role in tumor classification. Med Pharm Rep. 2023;96(4):384-91. doi: 10.15386/mpr-2639, PMID 37970196
Teroerde M, Nientiedt C, Duensing A, Hohenfellner M, Stenzinger A, Duensing S. Revisiting the role of p53 prostate cancer. In: Bott SR, Ng KL, editors. Prostate Cancer. Brisbane AU: Exon Publications; 2021.
Wahid Z, Jaffer R, Khalid S, Khan HA, Riaz S. Expression of p53 protein in prostate carcinoma and its correlation with Gleason grade. J Coll Physicians Surg Pak. 2020;30(6):643-5. doi: 10.29271/ jcpsp.2020.06.643, PMID 32703352
Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: Mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92. doi: 10.1038/s41392-023-01347-1, PMID 36859359
Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556. doi: 10.1016/j.bbcan.2021.188556, PMID 33932560
Published
How to Cite
Issue
Section
Copyright (c) 2024 Aditi Pal, Mahendra Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
